decad
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
occurr
novel
cov
term
middl
east
respiratori
syndrom
mer
cov
challeng
research
public
health
author
control
spread
final
contain
novel
virus
rapid
identif
subsequ
isol
infect
individu
contact
utmost
import
next
method
nucleic
acid
detect
valid
serolog
assay
particularli
import
timefram
antibodi
detect
less
restrict
sarscov
epidem
wide
varieti
serolog
diagnost
assay
establish
use
multipl
method
well
differ
viral
antigen
even
though
major
develop
assay
show
high
sensit
specif
numer
studi
report
crossreact
antibodi
antigen
widespread
common
cold
associ
cov
order
improv
prepared
respons
futur
outbreak
novel
cov
inform
problem
regard
serolog
diagnosi
occur
sarscov
acknowledg
review
summar
perform
differ
serolog
assay
well
applic
two
main
appli
antigen
spike
nucleocapsid
protein
use
sarscov
outbreak
highlight
challeng
potenti
pitfal
occur
deal
novel
emerg
coronaviru
like
merscov
addit
describ
problem
might
occur
anim
sera
test
serolog
assay
identif
put
reservoir
final
give
recommend
serolog
test
scheme
outlin
necessari
improv
implement
better
prepared
new
diseas
emerg
southeast
asia
subsequ
term
sever
acut
respiratori
syndrom
sar
previous
unknown
coronaviru
cov
identifi
etiolog
agent
ksiazek
et
al
peiri
et
al
concert
effort
public
health
author
made
possibl
break
chain
transmiss
new
case
report
sinc
may
overal
sarscov
infect
peopl
die
give
case
fatal
ratio
chanyeung
xu
emerg
sarscov
human
pathogen
cov
hcov
known
caus
mild
upper
respiratori
diseas
contribut
season
common
cold
case
diagnost
assay
sarscov
detect
rapidli
develop
identif
viru
test
suspect
case
help
consider
contain
outbreak
understand
rapid
diseas
progress
observ
patient
sar
patient
detect
viral
rna
three
day
first
symptom
appear
high
viral
load
lower
respiratori
tract
fecal
sampl
quantit
realtim
revers
transcript
polymeras
chain
reaction
qrtpcr
assay
first
assay
help
identifi
subsequ
isol
patient
activ
shed
viru
report
viral
rna
could
detect
qrtpcr
day
post
onset
ill
dpoi
howev
detect
rate
earli
qrtpcr
assay
often
low
reli
sampl
viru
shed
proper
handl
sampl
specif
qrtpcr
assay
also
question
potenti
nucleic
acid
contamin
laboratori
mani
sarscov
sampl
process
patrick
et
al
consequ
develop
serolog
assay
becam
crucial
time
mani
laboratori
worldwid
gener
inhous
assay
use
either
virusderiv
antigen
recombin
structur
cov
protein
laboratori
proper
valid
serolog
assay
highli
challeng
relianc
numer
wellcharacter
posit
neg
serum
sampl
furthermor
exchang
patient
serum
sampl
major
challeng
outbreak
logist
ethic
reason
assay
sensit
number
posit
sampl
could
determin
correctli
specif
measur
number
neg
sampl
could
identifi
correctli
therefor
difficult
determin
consequ
extern
qualiti
assur
studi
reveal
mani
laboratori
difficulti
sarscov
serodiagnost
particular
high
seropreval
popul
antibodi
common
cold
cov
combin
presenc
crossreact
antibodi
conserv
part
immunogen
cov
protein
could
contribut
fals
posit
result
nevertheless
antibodi
detect
long
period
develop
reliabl
postinfect
serolog
assay
sarscov
becam
high
prioriti
serodiagnost
assay
appli
address
epidemiolog
question
transmiss
pattern
observ
silent
infect
analyz
diseas
progress
identifi
origin
sarscov
patient
usual
develop
igm
igg
antibodi
within
dpoi
woo
et
al
identifi
infect
contact
includ
asymptomat
recommend
analyz
pair
serum
sampl
ideal
sampl
taken
day
day
post
exposur
sinc
shown
seroconvers
igg
igm
occur
period
accord
criteria
serolog
diagnosi
patient
consid
seroconvert
one
follow
statement
true
neg
antibodi
test
acutephas
serum
follow
posit
antibodi
test
convalescentphas
serum
test
parallel
fourfold
greater
rise
antibodi
titer
acuteand
convalescentphas
sera
test
parallel
note
recommend
use
viru
neutral
test
vnt
exclud
serolog
crossreact
human
anim
cov
review
summar
variou
type
serolog
assay
develop
sarscov
outbreak
analyz
challeng
potenti
pitfal
serodiagnost
acknowledg
multitud
develop
assay
lack
standard
procedur
assay
valid
make
difficult
directli
compar
studi
final
discuss
implic
challeng
face
serodiagnosi
novel
middl
east
respiratori
syndrom
merscov
test
differ
immunoglobulin
ig
subclass
common
serodiagnost
pentamer
ten
antigenbind
site
igm
character
higher
antigen
avid
lower
antigen
affin
igg
murphi
et
al
antibodi
igm
subclass
usual
first
develop
follow
primari
challeng
murphi
et
al
igm
consid
paramet
earli
phase
infect
howev
woo
et
al
found
igm
could
detect
earlier
iga
igg
subclass
antibodi
sarscov
serodiagnost
assay
low
affin
igm
antibodi
also
carri
increas
risk
crossreact
antigen
relat
epitop
common
cov
igm
detect
ad
valu
cov
serodiagnost
present
recent
infect
patient
allow
differenti
diagnosi
contrast
igg
antibodi
compris
higher
specif
igm
detect
even
year
infect
review
therefor
focu
studi
describ
assay
detect
igg
antibodi
outbreak
sarscov
wide
varieti
serolog
assay
establish
includ
immunofluoresc
assay
ifa
enzymelink
immunosorb
assay
elisa
western
blot
wb
analysi
convent
ifa
cifa
use
virusinfect
african
green
monkey
kidney
cell
vero
spot
glass
slide
elisa
use
extract
supernat
infect
cell
among
first
assay
use
serolog
diagnosi
sarscov
chen
et
al
hsueh
et
al
ksiazek
et
al
peiri
et
al
wu
et
al
cifa
elisa
sarscov
rel
easi
set
experienc
laboratori
primarili
requir
suscept
cell
cultur
viru
obviou
disadvantag
virusbas
serolog
assay
need
biosafeti
level
bsl
facil
addit
ifa
neither
properli
standard
interpret
fluoresc
stain
pattern
subject
appropri
highthroughput
screen
case
elisa
antigen
product
obstacl
necessit
ultracentrifug
condit
ensur
antigen
properli
inactiv
also
problemat
ultim
valid
elisa
depend
access
wellcharacter
serum
collect
determin
assayspecif
cutoff
valu
detail
summari
studi
appli
sar
virusbas
cifa
elisa
given
tabl
sinc
sarscov
seroconvers
gener
occur
second
week
ill
hsueh
et
al
ksiazek
et
al
studi
sera
taken
least
dpoi
includ
overview
major
case
patient
serum
test
assay
use
virusderiv
antigen
studi
found
serum
previous
diagnos
sar
patient
test
posit
tabl
column
suggest
cifa
elisa
use
highli
sensit
note
studi
reliabl
result
use
larg
number
patient
serum
sampl
n
chan
et
al
n
wu
et
al
found
respect
posit
specif
serolog
assay
vital
avoid
fals
posit
diagnos
critic
hcov
antigen
close
relat
bradburn
mean
combin
observ
high
preval
hcov
popul
che
et
al
dijkman
et
al
specif
sarscov
assay
particular
concern
therefor
analyz
summar
rate
fals
posit
result
found
serolog
studi
differenti
two
type
control
group
use
sera
individu
nonsar
respiratori
infect
contact
sar
patient
healthi
donor
tabl
column
one
limit
analysi
studi
neg
control
sera
obtain
respiratori
infect
patient
blood
donor
therefor
inclus
unidentifi
sar
case
complet
discount
nevertheless
detect
rate
fals
posit
sampl
give
rough
estim
specif
allow
perform
assay
evalu
variou
case
control
studi
conduct
sar
outbreak
cifa
viral
antigenbas
elisa
detect
fals
posit
tabl
column
assay
outcom
highli
depend
studi
design
neg
cohort
select
notabl
one
studi
rate
fals
posit
result
cifa
increas
viru
neutral
assay
use
gold
standard
wu
et
al
could
explain
lack
neutral
capac
certain
cifaposit
sera
inde
crossreact
sera
antigen
relat
hcov
cifa
studi
guan
colleagu
clearli
emphas
problem
encount
use
whole
virusderiv
antigen
appli
whole
viral
lysat
antigen
wb
analysi
observ
mark
differ
reactiv
individu
cov
protein
n
protein
reactiv
detect
sar
patient
sera
indic
sensit
howev
also
gave
fals
posit
result
case
depend
type
neg
control
subset
test
contrast
serum
sar
patient
react
protein
fals
posit
indic
protein
detect
wb
higher
specif
interestingli
one
studi
recombin
glutathion
transferas
gst
tag
n
protein
lack
highli
conserv
part
use
target
fals
posit
clearli
demonstr
serolog
assay
appli
sarscovderiv
antigen
interpret
caution
serolog
assay
reli
recombin
protein
antigen
wide
use
laboratori
diagnost
ecker
et
al
farber
et
al
prerequisit
singl
immunogen
viral
gene
clone
prokaryot
eukaryot
express
plasmid
produc
protein
bacteri
mammalian
cell
cultur
major
advantag
requir
contain
appropri
assay
standard
protocol
close
follow
sarscov
n
major
immunogen
protein
recombin
version
protein
use
ifa
elisa
wb
analysi
tabl
nevertheless
develop
valid
assay
use
recombin
protein
may
take
longer
also
technic
demand
necessari
molecular
clone
transfect
protein
purif
techniqu
must
first
optim
n
protein
major
immunogen
protein
sarscov
wide
use
recombin
serolog
assay
small
size
lack
glycosyl
site
make
easi
clone
purifi
vast
quantiti
bacteria
serum
sar
patient
react
complet
partial
n
protein
elisa
wb
analys
indic
assay
high
sensit
tabl
mark
differ
could
found
studi
use
partial
complet
n
protein
antigen
contrast
rate
fals
posit
result
differ
grossli
individu
studi
studi
claim
n
proteinbas
elisa
wb
analysi
detect
fals
posit
sera
neg
control
group
tabl
suggest
low
moder
specif
note
woo
et
al
abl
show
sera
fals
posit
n
proteinbas
elisa
reactiv
confirmatori
wb
assay
use
sar
spike
polypeptid
therefor
sera
confirm
truli
fals
posit
make
studi
reliabl
other
convers
sever
report
show
crossreact
human
pathogen
cov
occur
use
n
proteinbas
assay
che
et
al
maach
et
al
woo
et
al
particular
note
one
studi
n
protein
complet
fail
differenti
serum
sar
patient
healthi
individu
maach
et
al
find
highlight
complex
serum
diagnost
cov
emphas
valid
diagnosi
reli
reactiv
singl
antigen
protein
major
immunodomin
protein
sarscov
protein
use
ifa
elisa
wb
analysi
well
gener
pseudotyp
particl
develop
biosaf
vnt
fukushi
et
al
hofmann
et
al
major
neutral
antibodi
found
direct
protein
buchholz
et
al
ifa
possibl
use
fulllength
stabli
express
mammalian
cell
tan
et
al
fragment
amino
acid
aa
express
insect
cell
use
baculoviru
manopo
et
al
contrast
technic
difficulti
express
fulllength
protein
bacteria
fragment
use
elisa
wb
analysi
gener
antibodi
direct
protein
appear
later
infect
direct
n
protein
tan
et
al
woo
et
al
indic
proteinbas
assay
may
prefer
use
convalesc
sera
overal
reactiv
sar
patient
sera
protein
differ
grossli
differ
studi
type
assay
rang
low
one
studi
leung
et
al
sever
studi
tabl
mark
differ
detect
rate
ifa
elisa
wb
analysi
tabl
advantag
ifa
explain
use
transfect
cell
facilit
correct
fold
posttransl
modif
eg
glycosyl
protein
wherea
elisa
wb
analysi
use
denatur
linear
form
without
proper
glycosyl
glycoprotein
human
immunodefici
viru
hiv
shown
alter
glycosyl
pattern
influenc
host
immun
respons
grundner
et
al
therefor
patient
produc
mainli
antibodi
recogn
conform
epitop
glycosylationdepend
epitop
protein
could
test
fals
neg
elisa
wb
analysi
elisa
wb
analysi
abl
use
protein
fragment
mention
provid
plausibl
explan
variabl
result
found
differ
assay
reactiv
neg
control
sera
protein
vari
wide
individu
studi
two
studi
use
ifa
test
sizeabl
control
group
sera
detect
fals
posit
tabl
indic
high
specif
assay
contrast
elisa
wb
assay
report
fals
posit
result
although
studi
use
control
group
less
sera
make
less
reliabl
estim
true
perform
assay
interestingli
elisabas
studi
use
rather
larg
control
group
healthi
donor
found
two
fals
posit
serum
sampl
result
suggest
ifa
use
complet
protein
specif
advantag
elisa
wb
assay
immunogen
protein
close
relat
virus
share
common
structur
linear
epitop
elicit
crossreact
crossneutr
antibodi
host
occur
cov
recogn
mani
decad
bradburn
reflect
former
classif
cov
serogroup
mcintosh
et
al
monto
result
assay
use
full
viru
particl
extract
infect
cell
antigen
encount
sever
problem
two
studi
report
appear
band
molecular
weight
andor
kda
wb
assay
use
crude
viral
lysat
could
attribut
structur
protein
guan
et
al
leung
et
al
specul
band
might
repres
nsp
recogn
sar
patient
sera
fact
shown
nsp
accessori
orfencod
protein
incorpor
viral
particl
neuman
et
al
possibl
abl
elicit
immun
respons
inde
reactiv
antibodi
sarscov
protein
demonstr
sar
patient
protein
micro
array
antibodi
direct
conserv
nsp
orf
protein
could
contribut
fals
posit
result
assay
use
whole
viru
antigen
addit
conserv
structur
protein
n
protein
produc
high
level
infect
cell
viral
particl
increas
potenti
crossreact
differ
cov
influenc
n
protein
serolog
assay
outlin
detail
particularli
use
denatur
antigen
serodiagnost
assay
crossreact
like
occur
appli
target
protein
conserv
among
relat
virus
estim
rate
conserv
immunogen
protein
n
analyz
percentag
aa
ident
hcov
compris
genera
alphaand
betacov
tabl
first
column
pairwis
analysi
complet
n
sequenc
reveal
sarscov
n
protein
aa
ident
alphacov
close
relat
betacov
comparison
complet
protein
sequenc
show
lower
degre
conserv
aa
ident
alphacov
around
betacov
howev
antibodi
produc
expos
domain
threedimension
protein
overal
degre
aa
conserv
alon
predict
occurr
crossreact
gain
fuller
pictur
therefor
analyz
avail
inform
conserv
aa
sequenc
within
known
immunodomin
region
sarscov
n
protein
tabl
studi
chen
colleagu
reveal
four
immunodomin
region
n
protein
term
aa
aa
aa
aa
upon
comparison
human
pathogen
betacov
one
immunodomin
region
n
protein
show
low
degre
conserv
three
region
show
high
degre
tabl
addit
rota
et
al
found
conserv
motif
eight
amino
acid
present
n
protein
cov
includ
anim
cov
protein
harbor
five
differ
immunogen
site
aa
posit
et
al
compar
human
pathogen
betacov
three
immunodomin
region
protein
show
low
degre
conserv
one
region
show
medium
degre
one
region
show
high
degre
taken
togeth
find
may
explain
n
proteinbas
serolog
assay
often
associ
crossreact
proteinbas
assay
sever
studi
address
question
whether
crossneutr
relat
cov
crossneutr
shown
close
relat
anim
cov
transmiss
gastroenter
viru
tgev
felin
infecti
periton
viru
type
horzinek
et
al
around
ident
ctermin
aa
protein
also
bovin
cov
bcov
gerna
et
al
interestingli
even
close
relat
neither
neutral
sera
despit
aa
ident
protein
sera
reactiv
distantli
relat
sarscov
chan
et
al
similar
result
found
close
relat
cov
hofmann
et
al
knowledg
one
studi
describ
crossneutr
hcov
name
merscov
use
sarscov
reactiv
sera
howev
note
neutral
titer
low
indic
assayspecif
cutoff
determin
welldefin
refer
sera
avoid
fals
posit
result
chan
et
al
conclus
data
clearli
show
valu
vnt
tool
differenti
even
close
relat
cov
reaffirm
statu
gold
standard
serolog
diagnost
provid
valid
serolog
diagnosi
infect
cov
vital
rule
crossreact
crossneutr
use
second
confirmatori
assay
wide
accept
confirmatori
assay
like
vnt
recommend
sar
outbreak
laborintens
lead
high
workload
diagnost
laboratori
subsequ
slow
sampl
process
latter
particular
unfavor
outbreak
situat
rapid
identif
infect
individu
contact
necessari
contain
infecti
agent
establish
highli
specif
primari
serolog
screen
assay
avoid
fals
posit
result
thu
need
confirm
therefor
import
goal
serolog
assay
use
success
prescreen
tool
viru
discoveri
burbelo
et
al
drexler
et
al
muller
et
al
peel
et
al
antibodi
detect
assay
particularli
valuabl
short
phase
viru
shed
poor
sampl
qualiti
decreas
chanc
detect
nucleic
acid
addit
allow
distribut
pathogen
variou
speci
antigen
related
alreadi
known
pathogen
defin
drexler
et
al
importantli
test
livestock
wild
anim
help
trace
sourc
infect
outbreak
zoonot
viru
identif
anim
reservoir
allow
pathogen
contain
interrupt
chain
transmiss
exampl
shut
anim
market
cull
infect
anim
success
approach
outbreak
avian
influenza
sarscov
kan
et
al
tam
tu
et
al
watt
zoonot
origin
sarscov
suspect
earli
first
case
occur
among
peopl
handl
wild
exot
anim
guangdong
provinc
china
zhong
et
al
shortli
afterward
guan
colleagu
acquir
first
evid
use
rtpcr
vnt
himalayan
palm
civet
paguma
larvata
raccoon
dog
nyctereut
procyanoid
harbor
sarscov
strain
ident
human
sarscov
strain
lack
viral
genet
divers
posit
anim
along
fact
wild
farm
palm
civet
sarscov
seroneg
tu
et
al
indic
palm
civet
natur
reservoir
sarscov
search
sourc
sarscov
continu
screen
hundr
anim
multitud
speci
poon
et
al
decad
later
natur
reservoir
sarscov
eventu
confirm
rhinolophu
sinicu
bat
china
ge
et
al
valuabl
hint
facilit
identif
sarscov
reservoir
alreadi
provid
late
two
studi
found
close
relat
sarscov
chines
rhinolophid
bat
asia
rtpcr
serolog
method
li
et
al
anoth
studi
found
distantli
relat
cov
bat
famili
poon
et
al
li
et
al
use
two
differ
elisa
recombin
sarscov
n
proteinand
whole
viru
antigenbas
detect
seropreval
depend
bat
speci
second
studi
lau
et
al
use
elisa
wb
analysi
base
recombin
n
protein
deriv
bat
sarslik
cov
found
seropreval
elisa
wb
bat
mark
differ
two
studi
observ
neutral
activ
bat
sera
toward
human
sarscov
lau
et
al
could
detect
neutral
antibodi
bat
sera
li
et
al
found
neutral
activ
despit
posit
serum
titer
elisa
despit
differ
studi
indic
high
level
crossreact
antibodi
complet
viru
antigenand
recombin
n
proteinbas
assay
use
vnt
show
higher
specif
even
close
relat
cov
sever
followup
studi
bat
conduct
find
first
evid
cov
african
bat
came
detect
antibodi
react
sarscov
protein
muller
et
al
differ
serolog
assay
employ
red
hi
gh
degre
green
low
degre
includ
sarscov
proteinbas
elisa
cifa
use
sarscov
infect
cell
wb
assay
use
either
recombin
n
protein
whole
viru
antigen
muller
et
al
case
vnt
reveal
african
bat
harbor
antibodi
crossreact
differ
sarscov
antigen
abl
neutral
sarscov
subsequ
studi
other
found
alphaand
betacoronavirus
highli
divers
african
bat
pfefferl
et
al
quan
et
al
includ
close
ancestr
rel
distant
rel
sarscov
exampl
show
detect
crossreact
bat
serum
antibodi
sarscov
antigen
result
discoveri
highli
divers
bat
cov
includ
rel
sarscov
conclus
assay
perform
well
anim
sera
howev
outcom
evalu
cautious
test
anim
sera
add
anoth
level
complex
anim
may
harbor
antibodi
unidentifi
cov
crossreact
target
antigen
especi
without
know
degre
epitop
conserv
test
antigen
unidentifi
cov
mani
case
secondari
detect
antibodi
alway
avail
perform
serolog
assay
valid
particularli
true
human
serodiagnost
assay
modifi
use
anim
screen
absenc
viral
nucleic
acid
outcom
serolog
anim
screen
interpret
cautious
use
initi
indic
target
followup
studi
june
previous
unknown
cov
term
merscov
emerg
middl
east
zaki
et
al
date
peopl
infect
die
result
case
fatal
ratio
far
viru
endem
middl
east
case
import
countri
outsid
region
bermingham
et
al
buchholz
et
al
drosten
et
al
gueri
et
al
hpa
puzelli
et
al
similar
sar
outbreak
first
diagnost
assay
includ
pcr
serolog
develop
rapidli
corman
et
al
corman
et
al
differ
serolog
assay
establish
includ
cifa
use
virusinfect
cell
ifa
use
vero
cell
express
recombin
n
protein
merscov
well
wb
analysi
lysat
cell
express
recombin
n
protein
corman
et
al
cellfre
protein
microarray
develop
use
correctli
fold
glycosyl
fragment
merscov
protein
antigen
reusken
et
al
final
merscovand
proteinpseudotyp
virus
use
neutral
assay
buchholz
et
al
drosten
et
al
gierer
et
al
perera
et
al
major
problem
face
group
time
assay
develop
need
wellcharacter
serum
sampl
collect
enabl
thorough
valid
includ
defin
posit
sera
known
human
pathogen
cov
merscov
convalesc
sera
along
neg
control
group
small
number
posit
sera
avail
time
test
determin
assay
sensit
current
requir
rigor
valid
assay
specif
address
studi
similar
sarscov
serolog
assay
use
whole
viru
recombin
n
protein
gave
fals
posit
result
igm
detect
buchholz
et
al
anoth
studi
serum
sampl
includ
slaughterhous
worker
saudi
arabia
screen
use
cifa
follow
recombin
proteinbas
ifa
vnt
confirm
cifa
studi
produc
signific
number
fals
posit
requir
exclus
confirmatori
neutral
assay
aburizaiza
et
al
anoth
studi
conduct
saudi
arabia
made
use
merss
pseudotyp
lentivirus
test
virusneutr
antibodi
gierer
et
al
pseudotyp
virus
use
control
test
serum
sampl
neg
merscov
neutral
antibodi
unspecif
crossneutr
merss
pseudotyp
virus
sera
anoth
studi
compar
convent
vnt
pseudotyp
lentivirusbas
nt
total
human
serum
sampl
collect
healthi
donor
egypt
control
hong
kong
neg
nt
format
perera
et
al
studi
emphas
nt
less
prone
unspecif
reactiv
use
pseudotyp
virus
ad
advantag
requir
laboratori
largescal
serolog
studi
popul
affect
countri
urgent
need
examin
spread
preval
transmiss
merscov
despit
sever
attempt
find
sourc
outbreak
origin
merscov
remain
enigmat
sever
studi
base
nucleic
acid
detect
assay
found
close
relat
cov
differ
bat
speci
africa
saudi
arabia
northern
america
anthoni
et
al
ithet
et
al
memish
et
al
parallel
pcrbase
method
took
serolog
approach
screen
livestock
anim
merscovlink
oman
unlink
region
spain
netherland
show
test
dromedari
camel
oman
well
camel
canari
island
harbor
merscov
neutral
antibodi
reusken
et
al
canari
island
link
mer
case
find
surpris
addit
abl
identifi
merscov
specif
antibodi
camel
sera
unit
arab
emir
uae
collect
year
ago
importantli
sinc
bcov
betacov
lineag
commonli
distribut
among
livestock
crossneutr
merscov
bcov
antibodi
exclud
recent
studi
haagman
colleagu
could
verifi
merscov
infect
camel
farm
human
case
occur
use
rtpcr
detect
method
haagman
et
al
still
sinc
genet
distanc
human
camel
merscov
cluster
small
possibl
differenti
whether
camel
infect
human
vice
versa
valu
merss
pseudotyp
lentivirusbas
nt
shown
independ
camel
studi
conduct
egypt
also
found
high
percentag
neutral
antibodi
anim
perera
et
al
conclus
data
highlight
problem
interpret
cov
serolog
assay
especi
whole
virusderiv
antigen
use
stress
demonstr
neutral
indispens
ultim
confirm
seroconvers
specif
cov
serolog
assay
proven
valuabl
multitud
investig
particularli
complement
nucleic
acid
detect
assay
serolog
help
identif
sourc
infect
clarif
epidemiolog
includ
transmiss
pattern
analysi
patient
contact
studi
identif
asymptomat
case
task
achiev
specif
sensit
serolog
assay
howev
properli
valid
assay
wellcharacter
serum
sampl
patient
necessari
avail
outbreak
scenario
despit
larg
number
assay
develop
aftermath
outbreak
sarsand
merscov
serolog
differenti
hcov
remain
challeng
overal
conclud
problem
crossreact
like
aris
conserv
antigen
often
manifest
fals
posit
result
whether
elisa
wb
assay
prefer
screen
tool
depend
avail
molecular
biolog
techniqu
exact
studi
design
well
number
sampl
compar
whole
viru
antigen
assay
use
recombin
protein
gener
reliabl
easili
standard
prefer
recombin
serolog
assay
use
antigen
highli
immunogen
provid
epitop
specif
viru
speci
addit
import
protein
express
natur
conform
ie
display
proper
fold
glycosyl
discuss
case
coronavirus
protein
combin
featur
regardless
assay
antigen
use
recommend
thorough
valid
use
defin
set
sera
reactiv
hcov
well
larg
number
neg
serum
sampl
patient
respiratori
diseas
case
great
care
taken
select
appropri
assay
limit
assay
consid
interpret
result
opinion
ultim
confirm
serolog
result
indispens
perform
vnt
specif
assay
avail
improv
coordin
develop
serolog
assay
futur
outbreak
novel
coronavirus
wellcharacter
subset
sera
would
highli
recommend
order
implement
standard
protocol
valid
new
assay
